Targeting thrombopoietin to treat blood cancers
Thrombopoietin Targeting in Myeloproliferative Neoplasms
This study is testing a new drug called AB062 to help people with myeloproliferative neoplasms (MPNs) by lowering the levels of a protein that causes too many blood cells to be made, which could lead to better health and a better quality of life for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aronora, INC. NIH-funded |
| Lab location | 1 site (Portland, UNITED STATES) |
| Project ID | NIH-10875331 on NIH RePORTER |
What this research studies
This research focuses on developing a new treatment for patients with myeloproliferative neoplasms (MPNs), a type of blood cancer characterized by the overproduction of blood cells. The approach involves using a novel drug candidate, AB062, which is an antisense oligonucleotide designed to inhibit the production of thrombopoietin, a protein that stimulates blood cell production. By reducing thrombopoietin levels, the treatment aims to decrease the number of abnormal blood cells while preserving healthy blood cell production. This could potentially improve patient outcomes and quality of life for those suffering from advanced MPNs.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with myeloproliferative neoplasms, particularly those who have not responded well to existing treatments.
Not a fit: Patients with early-stage MPNs or those who do not have a confirmed diagnosis of myeloproliferative neoplasms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option that significantly improves survival and quality of life for patients with myeloproliferative neoplasms.
How similar studies have performed: While the approach of targeting thrombopoietin is innovative, similar strategies in the field of blood cancers have shown promise, indicating potential for success.
Where this research is happening
Portland, UNITED STATES
- Aronora, INC. — Portland, United States (Active)
Researchers
- Principal investigator: Lorentz, Christina U — Aronora, INC.
- Study coordinator: Lorentz, Christina U
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.